Targeting USP9X–AMPK Axis in ARID1A-Deficient Hepatocellular CarcinomaSummary
Background & Aims: Hepatocellular carcinoma (HCC) is a highly heterogeneous solid tumor with high morbidity and mortality. AT-rich interaction domain 1A (ARID1A) accounts for up to 10% of mutations in liver cancer, however, its role in HCC remains controversial, and no targeted therapy has b...
Main Authors: | Feng-Kun Zhang, Qian-Zhi Ni, Kang Wang, Hui-Jun Cao, Dong-Xian Guan, Er-Bin Zhang, Ning Ma, Yi-Kang Wang, Qian-Wen Zheng, Sheng Xu, Bing Zhu, Tian-Wei Chen, Ji Xia, Xiao-Song Qiu, Xu-Fen Ding, Hao Jiang, Lin Qiu, Xiang Wang, Wei Chen, Shu-Qun Cheng, Dong Xie, Jing-Jing Li |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2022-01-01
|
Series: | Cellular and Molecular Gastroenterology and Hepatology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S2352345X22000613 |
Similar Items
-
Genetic analysis of sinonasal undifferentiated carcinoma discovers recurrent SWI/SNF alterations and a novel PGAP3-SRPK1 fusion gene
by: Molly E. Heft Neal, et al.
Published: (2021-05-01) -
AURKA inhibition shows promise as a therapeutic strategy for ARID1A-mutant colorectal cancer
by: Rong-Sheng Qin, et al.
Published: (2024-10-01) -
ARID2 Chromatin Remodeler in Hepatocellular Carcinoma
by: Robin Loesch, et al.
Published: (2020-09-01) -
Acetate supplementation restores cognitive deficits caused by ARID1A haploinsufficiency in excitatory neurons
by: Pei‐Pei Liu, et al.
Published: (2022-11-01) -
Selective vulnerability of ARID1A deficient colon cancer cells to combined radiation and ATR-inhibitor therapy
by: Shan Xu, et al.
Published: (2022-09-01)